Our study further confirmed these soluble molecules (CD28, CXCL10, TNFRSF9, TNFSF14, CD83, and HVEM) as predictive biomarkers in NSCLC, and might be potential targets to boost immunotherapy in patients. This evidence concerns the gene TNFRSF14 and non-small cell lung carcinoma.